Schizophrenia Pipeline Therapeutics Market Report in H1 2017 May 2017

Schizophrenia Pipeline Therapeutics Market Report for Companies and Drug
Profile in H1 2017
The Schizophrenia Pipeline Market Review, H1 2017, provides an overview of the
Schizophrenia (Central Nervous System) pipeline landscape. The Schizophrenia Market Report
provides a pipeline guide reviews for key companies involved in Schizophrenia (Central Nervous
System) therapeutics and enlists all their major and minor projects.
Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late
adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized
speech and disorganized behavior. Risk factors include family history, age, drugs (psychoactive)
and weakened immune system. Treatment includes antipsychotic medications.
Get Discount on this Research Report at
http://www.reportsnreports.com/contacts/discount.aspx?name=1010755 – This report is
available at up to 25% Discount till June 02nd 2017.
Pharmaceutical and Healthcare latest pipeline guide Schizophrenia - Pipeline Review, H1 2017,
provides comprehensive information on the therapeutics under development for Schizophrenia
(Central Nervous System), complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers
the descriptive pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.
The latest Pharmaceutical and Healthcare disease pipeline guide Schizophrenia - Pipeline
Review, H1 2017, provides an overview of the Schizophrenia (Central Nervous System) pipeline
landscape. The Key Company Profiles are Aequus Pharmaceuticals Inc, Astellas Pharma Inc,
Omeros Corp, Pfizer Inc, Merck & Co Inc.
The guide covers therapeutics under Development by Companies /Universities /Institutes, the
molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA
Filed, Preclinical, Discovery and Unknown stages are 4, 12, 13, 22, 1, 54, 10 and 2 respectively.
Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 9
and 2 molecules, respectively.
Inquire more on this Research Report at
http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=1010755
Schizophrenia (Central Nervous System) pipeline guide helps in identifying and tracking
emerging players in the market and their portfolios, enhances decision making capabilities and
helps to create effective counter strategies to gain competitive advantage. The guide is built
using data and information sourced from databases, company/university websites, clinical trial
registries, conferences, SEC filings, investor presentations and featured press releases from
www.reportsnreports.com